Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

• Published in: Nature medicine Vol. 29; no. 10; pp. 2518 - 2525
• Main Authors: Grillo, Sara, Pujol, Miquel, Miró, Josep M., López-Contreras, Joaquín, Euba, Gorane, Gasch, Oriol, Boix-Palop, Lucia, Garcia-País, Maria José, Pérez-Rodríguez, Maria Teresa, Gomez-Zorrilla, Silvia, Oriol, Isabel, López-Cortés, Luis Eduardo, Pedro-Botet, Maria Luisa, San-Juan, Rafael, Aguado, José María, Gioia, Francesca, Iftimie, Simona, Morata, Laura, Jover-Sáenz, Alfredo, García-Pardo, Graciano, Loeches, Belén, Izquierdo-Cárdenas, Álvaro, Goikoetxea, Ane Josune, Gomila-Grange, Aina, Dietl, Beatriz, Berbel, Damaris, Videla, Sebastian, Hereu, Pilar, Padullés, Ariadna, Pallarès, Natalia, Tebé, Cristian, Cuervo, Guillermo, Carratalà, Jordi
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01-10-2023; Nature Publishing Group
• Subjects: 692/308/2779/777; 692/700/565/1436/2774; Bacteremia; Biomedical and Life Sciences; Biomedicine; Cancer Research; Clinical trials; Cloxacillin; Fosfomycin; Heterogeneity; Infectious Diseases; Intravenous administration; Metabolic Diseases; Methicillin; Molecular Medicine; Neurosciences; Patients; Randomization; Staphylococcus aureus; Success
• ISSN: 1078-8956; 1546-170X
• DOI: 10.1038/s41591-023-02569-0

Treatment failure occurs in about 25% of patients with methicillin-susceptible
Staphylococcus

aureus
(MSSA) bacteremia. We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with MSSA bacteremia. We conducted a multicenter, open-label, phase III–IV superiority randomized clinical trial. We randomly assigned patients (1:1) to receive 2 g of intravenous cloxacillin alone every 4 h or with 3 g of intravenous fosfomycin every 6 h for the initial 7 days. The primary endpoint was treatment success at day 7, a composite endpoint with the following criteria: patient alive, stable or with improved quick Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA, adjudicated by an independent committee blinded to treatment allocation. We randomized 215 patients, of whom 105 received cloxacillin plus fosfomycin and 110 received cloxacillin alone. We analyzed the primary endpoint with the intention-to-treat approach in 214 patients who received at least 1 day of treatment. Treatment success at day 7 after randomization was achieved in 83 (79.8%) of 104 patients receiving combination treatment versus 82 (74.5%) of 110 patients receiving monotherapy (risk difference 5.3%; 95% confidence interval (CI), –5.95–16.48). Secondary endpoints, including mortality and adverse events, were similar in the two groups except for persistent bacteremia at day 3, which was less common in the combination arm. In a prespecified interim analysis, the independent committee recommended stopping recruitment for futility prior to meeting the planned randomization of 366 patients. Cloxacillin plus fosfomycin did not achieve better treatment success at day 7 of therapy than cloxacillin alone in MSSA bacteremia. Further trials should consider the intrinsic heterogeneity of the infection by using a more personalized approach. ClinicalTrials.gov registration:
NCT03959345
.
New treatments are essential for methicillin-susceptible
Staphylococcus

aureus
bacteremia, but progress is slow. In this phase III–IV trial, cloxacillin plus fosfomycin failed to show superiority over cloxacillin alone, underscoring the challenges to improving patient outcomes.